BCL2 and neoplasm: The importance of Bcl-xL as a mediator of acute resistance to KRASG12C inhibitors was shown in vivo, where combined treatment of KRASG12CMT colorectal cancer xenografts with the BCL-2/Bcl-xL and KRASG12C inhibitors, navitoclax and AZ’8037, resulted in supraadditive reductions in tumor growth or regression.